NYSEAMERICAN : APUS
Apimeds Pharmaceuticals US, Inc. — Financial statements
Healthcare · Drug Manufacturers - Specialty & Generic · United Arab Emirates
Last price 2.94 USD (Nov 2, 2026, 10:42 AM EST) · Market cap 4.44M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 3.88M | 1.28M | 648.89K | 271.53K | 529.55K |
| Research & Development | 1.27M | 98.54K | 368.00K | 489.94K | |
| Operating Expenses | 5.15M | 1.28M | 747.44K | 639.53K | 1.02M |
| Operating Income | -5.15M | -1.28M | -747.44K | -639.53K | -1.02M |
| Interest Expense | -103.44K | -117.72K | -38.07K | -29.14K | -6.74K |
| Interest & Investment Income | 71.71K | 2.82K | 7.81K | ||
| Pretax Income | -5.16M | -1.39M | -777.69K | -668.67K | -1.03M |
| Net Income | -5.16M | -1.39M | -777.69K | -668.67K | -1.03M |
| Net Income to Common | -5.16M | -1.39M | -777.69K | -668.67K | -1.03M |
| Shares Outstanding (Basic) | 9.71M | 7.90M | 4.60M | 3.85M | 3.85M |
| Shares Outstanding (Diluted) | 9.71M | 7.90M | 4.60M | 3.85M | 3.85M |
| EPS (Basic) | -0.53 | -0.18 | -0.17 | -0.17 | -0.27 |
| EPS (Diluted) | -0.53 | -0.18 | -0.17 | -0.17 | -0.27 |
| EBIT | -5.15M | -1.28M | -747.44K | -639.53K | -1.02M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.99M | 3.46K | 410.48K | 6.17K | 171.44K |
| Cash & Short-Term Investments | 6.99M | 3.46K | 410.48K | 6.17K | 171.44K |
| Prepaid Expenses | 2.10M | 9.60K | 11.60K | 731.00 | |
| Total Current Assets | 9.09M | 13.06K | 422.08K | 6.17K | 172.17K |
| Total Assets | 9.25M | 13.06K | 422.08K | 6.17K | 172.17K |
| Accounts Payable | 3.66K | 10.65K | |||
| Accrued Expenses | 233.28K | 697.83K | 123.32K | 35.88K | |
| Short-Term Debt | 500.10K | 326.50K | 282.90K | ||
| Current Income Taxes Payable | 1.00K | ||||
| Total Current Liabilities | 1.09M | 1.02M | 123.32K | 319.78K | 10.65K |
| Long-Term Debt | 346.84K | 266.89K | 400.00K | 400.00K | |
| Total Liabilities | 1.09M | 1.37M | 390.21K | 719.78K | 410.65K |
| Common Stock | 125.76K | 79.04K | 79.04K | 100.00K | 100.00K |
| Additional Paid-In Capital | 17.27M | 2.95M | 2.95M | 1.41M | 1.22M |
| Retained Earnings | -9.24M | -4.39M | -3.00M | -2.22M | -1.56M |
| Shareholders' Equity | 8.16M | -1.36M | 31.87K | -713.61K | -238.48K |
| Total Liabilities & Equity | 9.25M | 13.06K | 422.08K | 6.17K | 172.17K |
| Total Debt | 500.10K | 673.34K | 266.89K | 682.90K | 400.00K |
| Net Cash (Debt) | 6.49M | -669.89K | 143.59K | -676.73K | -228.56K |
| Net Cash Per Share | 0.67 | -0.08 | 0.03 | -0.18 | -0.06 |
| Filing Date Shares Outstanding | 12.58M | 8.19M | 7.90M | 5.77M | 3.85M |
| Total Common Shares Outstanding | 12.58M | 7.90M | 7.90M | 5.77M | 3.85M |
| Working Capital | 8.00M | -1.01M | 298.76K | -313.61K | 161.52K |
| Book Value Per Share | 0.65 | -0.17 | 0.00 | -0.12 | -0.06 |
| Tangible Book Value | 8.16M | -1.36M | 31.87K | -713.61K | -238.48K |
| Tangible Book Value Per Share | 0.65 | -0.17 | 0.00 | -0.12 | -0.06 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Net Income | -5.16M | -1.39M | -777.69K | -668.67K | -1.03M |
| Stock-Based Compensation | 1.93M | 69.99K | 193.54K | 193.54K | |
| Other Operating Activities | 81.06K | 117.72K | 38.07K | 29.14K | 6.74K |
| Change in Accounts Payable | 151.68K | 536.75K | 53.44K | -2.91K | 3.57K |
| Change in Other Net Operating Assets | -2.22M | 1.99K | -11.59K | 731.00 | -731.00 |
| Operating Cash Flow | -5.21M | -733.53K | -627.79K | -448.17K | -823.11K |
| Short-Term Debt Issued | 326.50K | 9.00K | 282.90K | ||
| Long-Term Debt Issued | 400.00K | ||||
| Total Debt Issued | 343.90K | 326.50K | 9.00K | 282.90K | 400.00K |
| Short-Term Debt Repaid | -31.90K | ||||
| Total Debt Repaid | -93.80K | -31.90K | |||
| Net Debt Issued (Repaid) | 250.10K | 326.50K | -22.90K | 282.90K | 400.00K |
| Issuance of Common Stock | 11.95M | 1.05M | |||
| Financing Cash Flow | 12.20M | 326.50K | 1.03M | 282.90K | 400.00K |
| Net Cash Flow | 6.96M | -407.03K | 404.31K | -165.27K | -423.11K |
| Levered Free Cash Flow | -3.39M | -294.00K | -346.10K | -197.42K | |
| Unlevered Free Cash Flow | -3.33M | -220.42K | -322.31K | -179.21K | |
| Change in Working Capital | -2.07M | 538.75K | 41.84K | -2.18K | 2.84K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Debt / Equity Ratio | 0.06 | -0.50 | 8.38 | -0.96 | -1.68 |
| Quick Ratio | 6.41 | 0.00 | 3.33 | 0.02 | 16.09 |
| Current Ratio | 8.34 | 0.01 | 3.42 | 0.02 | 16.16 |
| Return on Assets (ROA) | -69.29% | -366.30% | -218.17% | -448.25% | |
| Return on Invested Capital (ROIC) | -78.61% | -348.55% | -611.12% | ||
| Return on Capital Employed (ROCE) | -63.10% | 126.10% | -250.20% | 203.90% | -631.20% |
| Buyback Yield / Dilution | -29.09% | -71.89% | -19.55% |